ISR Reports Releases "Risk-Based Monitoring: Industry Guidance on Adoption, Use, and Outsourcing"


Company News Release

Risk-based Monitoring: Industry Guidance on Adoption, Use, and Outsourcing

ISR believes the rise of risk-based monitoring (RBM) is a result of several forces acting on the pharmaceutical industry. First, electronic data capture (EDC) technology is now the de facto standard for site/ patient data capture. Second, the patent cliff and declining R&D productivity rates have conspired to “force” pharmaceutical companies to look at ways to cut costs, while increasing efficiency. Third, regulators have begun to output guidance documents that center on alternative drug development models and processes (risk-based monitoring, adaptive trials, electronic data as source data), making it less risky for sponsors to employ these methodologies/ strategies.

This report provides the pharmaceutical industry and its service providers with “peer-based” guidance and best-practices for the adoption, use, and outsourcing of risk-based monitoring. It contains:

  • 145 Pages

  • 78 Respondents

  • 83 Charts and Graphs

Major Report Sections:

  • Executive Summary

  • RBM Awareness and Definition

  • Best Practices & Operational Impact of RBM

  • Sponsor Perception and Use of RBM

  • Data and Technology

  • Outsourcing Environment

  • RBM Economics

  • Respondent Demographics

What You’ll Learn:

  • Sponsors’ interests in and use of RBM studies, why RBM is gaining momentum, what is driving adoption, and a high-level look at sponsors’ expected financial and operational outcomes of RBM studies

  • Real-world lessons-learned, including advice for individuals and companies wanting to implement RBM studies

  • Study types that are seen as most appropriate for RBM and which department are involved in the planning of these studies

  • On-the-ground suggestions for improving the RBM regulatory and training processes

  • Critical technologies are most important to running a successful RBM-based trial and which are most difficult to implement

  • The percentage of RBM studies outsourced, the preferred types of service providers, and most important service provider attributes effecting selection

Actionable Insight:

For sponsors: Use this information to help drive RBM adoption in your organization, avoid pitfalls that might stagger RBM growth, Inform your data infrastructure strategies, and benchmark the use of RBM.

For service providers: Better understand the inner working of sponsors as it relates to the adoption of RBM models and craft better messages and service offerings to account for these views.

Download the report here.



Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.